Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 75-year-old female patient was admitted to our department because of fever and right hypochondraligia. A giant tumor of the gallbladder was confirmed by CT scanning, ultrasonography and PTC. She underwent complete removal of the main tumor and right hemicolectomy. The extirpated tumor was solid, but partially occupied by coagulated and necrotic tissue, 13 X 11 X 9cm in size, and 900g in weight. On the basis of the histologic features of the tumor, MFH (pleomorphic type) originated from the gallbladder was clearly diagnosed. Her postoperative course was uneventful, but she died of cachexia due to recurrence on 79 days after operation. Malignant fibrous histiocytoma (MFH) is a soft tissue sarcoma, usually developing in the extremities, less commonly in the retroperitoneal and the abdominal cavity. MFH originated from the gallbladder is very rare, and only 3 cases were reported in Japan so far. This is the fourth reported case in Japan.
 ...
PMID:[Primary malignant fibrous histiocytoma of the gallbladder: a case report]. 284 5

Involvement of platelet membrane glycoproteins (GP) in interactions between platelets and tumor cells was studied by using two human tumor cell lines and two monoclonal antibodies against platelet membrane GP. HMV-I cells derived from vaginal melanoma induced platelet aggregation in heparinized plasma, which was not followed by coagulation. M7609 cells derived from colon adenocarcinoma also induced platelet aggregation in heparinized plasma, which, on the contrary, was followed by coagulation. Aggregating activities of the HMV-I cells were abolished by pretreatment with neuraminidase or trypsin, but M7609 activity was not labile to these enzymes. Aggregations induced by M7609 were inhibited by hirudin or MD805, while those by HMV-I were not. M7609 cells dose dependently shortened the recalcification time of normal as well as Factor IX-deficient plasmas, while they were not effective in shortening the time of Factor II- or Factor VII-deficient plasmas. The procoagulant activity of HMV-I cells was 1000 times less than M7609 on the basis of cell numbers. When human platelets were preincubated with monoclonal anti-GPIb or anti-GPIIb/IIIa complex antibodies, neither cell line could cause aggregations. These findings suggest that both GPIb and the GPIIb/IIIa complex on the platelet surface are involved in the thrombin-dependent and -independent platelet aggregations induced by tumor cells.
 ...
PMID:Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. 291 Apr 73

Ten patients with hepatocellular carcinoma (HCC) received intra-tumoral injection of OK-432 (6 patients), 99.5% ethanol (2 patients) or both (2 patients). Under ultrasonographic control, a PTC needle (22 G) was inserted percutaneously into the tumor and OK-432, which was prepared with a solution of Su-strain Streptococcus pyogenes A3, or 99.5% ethanol was injected. Patients were injected with OK-432 repeatedly at one-to two-week intervals (up to 5 times) for a total duration of 5 to 15 weeks. The degree of skin test reaction for Streptococcus pyogenes was increased in all patients after the treatment. Over 40% tumor regression was noted in 6 out of 9 patients who received intra-tumoral injection of OK-432. Complete regression was noted in one patient. Before treatment, Interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cell activity in peripheral blood lymphocytes decreased in HCC patients. Two of 6 patients showed markedly increased activity of LAK-cells one week after treatment with OK-432. One other patient had moderately increased LAK-cell activity after treatment with OK-432. No increase in LAK-cell activity was seen in 3 patients who received intra-tumoral injection of ethanol. An especially increased response of LAK-cell activity was seen in patients with small-sized HCC (diameter below 5 cm).
 ...
PMID:[Intra-tumoral injection therapy in patients with hepatocellular carcinoma]. 301 38

The diagnosis and treatment of 18 patients with carcinoma of the extrahepatic bile duct are reported. All patients were worked up by USG, PTC or ERC before operation. Tumor was resected in 3 patients, palliative internal or external drainage of the biliary tract was performed in 10, 1 was explored and 4 received PTCD treatment. One of the patients with the tumor resected has survived for 2 years. Mean survival time after the operation was 5.6 months for patients treated by drainage. The authors believe that PTC and ERC play the most important role in diagnosing carcinoma of the biliary tract. As this tumor has a low resection rate, internal or external drainage of the biliary tract should be done for patients with unresectable lesions. PTCD is still one of the effective palliative therapies for inoperable lesions.
 ...
PMID:[Carcinoma of the extrahepatic bile duct]. 341 3

The records of 121 patients who presented for PTC and biliary drainage within a five-year period were reviewed. Fifty-eight bile samples had been obtained from 38 of these patients for cytologic analysis. Malignancy was detected in 14 of 32 patients with carcinoma (sensitivity 44%). Repeat sampling was positive in four of nine patients whose initial specimen contained no tumor cells. Bile duct carcinoma, pancreatic carcinoma, and metastatic disease were all detected. An approach to biliary cytodiagnosis is offered that, it is hoped, will further minimize future false negative results.
 ...
PMID:Biliary cytodiagnosis. Bile sampling for cytology. 398 69

A 17-year-old male with previously undiagnosed congenital Factor IX deficiency (13%) presented with gastrointestinal bleeding and a hepatic mass. Prolonged thrombin and Reptilase times, which partially corrected with CaCl2 and a discrepancy between thrombin-clottable and immunoreactive plasma fibrinogen, suggested a dysfibrinogenemia. Laparotomy disclosed metastatic hepatoma. Adequate hemostasis was obtained with clotting factor replacement, but wound healing was delayed. Patient fibrinogen purified with 2.1 M glycine migrated normally on immunoelectrophoresis and 7.5% polyacrylamide-SDS gel electrophoresis. However, fibrin monomers prepared from purified patient fibrinogen displayed impaired aggregation at high and low ionic strengths when compared with fibrin monomers from normal and control Factor IX deficient subjects. Aggregation of normal monomers was delayed when mixed 1:1 with patient monomers. Fibrinopeptide release was normal, and total sialic acid content was similar to that of normal and control fibrinogens. Chemotherapy, consisting of 5-FU given via intra-arterial hepatic infusion, was accompanied by significant transient clinical improvement which coincided with correction of thrombin clotting times and fibrin monomer aggregation. Reappearance of fibrinogen dysfunction occurred with clinical deterioration prior to death from metastatic hepatoma and sepsis. This case is the first to corroborate the postulated tumor marker role of dysfibrinogenemia in a patient with hepatoma by documenting a direct relationship with response to chemotherapy.
 ...
PMID:Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy. 626 56

Biliary tract is the most suitable for sonographic diagnosis. That is caused by the biliary structure composing of bile and ductal system. Therefore, sonographic diagnosis of biliary tumor also is not so difficult. Careful observation of total biliary wall is necessary for diagnosis of the resectable small tumor. On the other hand, sonographic detection of advanced large tumor is easy. In the case of large tumor, the diagnosis of benign or malignant also is easy, but that of originating organ is rather difficult. However, in the case of small nodule or papillary tumor of biliary system, the detection of that is fairly difficult and the diagnosis of benign or malignant is more difficult. In the case of obstructing jaundice also, the ascertain of the end of dilated biliary duct is easy, and the detection of the tumor is not so difficult, but the diagnosis of benign or malignant is difficult. Therefore if the small nodule or papillary tumor in the biliary system was detected by the sonographic diagnosis, the following decision should be taken, suitably and promptly, that is the selection of the next one or more out of following many diagnostic modalities. There are ERCP, PTC, PTCD, angiography, sonographic guided biopsy or puncture, or laparatomy and so on.
 ...
PMID:[Sonographic diagnosis of biliary tumor]. 670 27

PTC, a mixture of oligopeptides of m-L-sarcholysin, acting primarily as an alkylating agent, was utilized as initial therapy following diagnosis in 80 children with nonlocalized neuroblastoma. Of the 67 evaluable patients (21 Stage III, 41 Stage IV and five Stage IV-S), 51 had measurable lesions allowing to evaluate PTC activity; objective tumor responses to the drug were recorded in 45 of these 51 cases (88.2%); 5/5 Stage III, 37/41 Stage IV, 3/5 Stage IV-S. Complete responses were obtained in seven patients (13.7%), partial responses in 32 (62.7%), objective improvement in six (11.8%). Four patients (7.8%) had either no tumor change, or tumor progression. There have been two early drug-related deaths (3.9%). Stage III and IV patients responding to PTC were then treated by irradiation + VCR, followed by cycles of a combination of ADriamycin, vincristine, and cyclophosphamide. Stage IV-S patients received no further therapy. Thirteen of 21 Stage III (61.9%), five of 41 Stage IV (12.2%) and four of five Stage IV-S (80%) are presently alive from 19-48 months (median, 27 months). PTC is an effective agent in advanced neuroblastoma. However, the results of this report do not indicate that its addition to a "standard" treatment, at least in the schedule adopted in this protocol, has improved the final outcome of children with nonlocalized disease.
 ...
PMID:Effect of peptichemio in nonlocalized neuroblastoma. 708 13

We report a patient with cystadenoma of the liver who presented with jaundice and abdominal mass. Although cystadenoma of the liver is a rare neoplasm, the lesion was diagnosed preoperatively by gray scale ultrasonography, PTC and ERCP. Characteristically, cystadenoma shows a multiseptated cystic appearance. While the origin of a cystadenoma is unclear, theories of synchronous development from anomalous bile ducts, endodermal diverticula, and ectopic germ cell origins have been promoted. Approximately 85% of patients with hepatic cystadenoma are women, with an insidious onset of symptoms due to the slowly growing nature of this tumor. Common symptoms include right upper quadrant mass, abdominal distension, and dull abdominal pain. Jaundice is less common. Complications include biliary obstruction, infection, hemorrhage, and rupture. As hepatic cystadenoma tends to recur after inadequate excision, and has malignant transformation potential, hepatic lobectomy has been promoted as definitive treatment.
 ...
PMID:Cystadenoma of the liver. 708 9

Mutational changes in the p53 tumor suppressor gene are the most frequent genetic alterations in human malignant tumors. Studies have shown a correlation of p53 expression in breast cancer with tumor prognosis. In contrast to mutational activation of ras and GSP in thyroid tumors, little is known about the role of p53 in thyroid tumor development. Therefore thyroid tumors and thyroid tumor cell lines were studied for the presence of p53 mutations. Snap-frozen tissues from 57 differentiated thyroid carcinomas (DTCs) and 5 goiters were studied by immunohistochemical methods. A panel of six antibodies (pAb 240, 421, 1620, 1801, DO7, and CM1) was employed by using the ABC technique. Five cell lines from DTCs (FTC133, 236, 238, PTC337, MTC164) were examined by the same technique. Additionally, genomic DNA from the cells was amplified by the polymerase chain reaction (PCR) and the PCR product studied for p53 mutations (R273H) by mutation-specific oligonucleotide hybridization (MOH) and temperature gradient gel electrophoresis (TGGE) for the p53 exon 8. None of the benign thyroid tumors and 7 of 57 (12%) DTCs strongly express p53 with a heterogeneous distribution in the tumor tissue. All seven patients have metastatic disease or dedifferentiated tumors G3 (three of seven). CM1 was positive in two cell lines (FTC-133, PTC-337), questionable in FTC-238, and negative in FTC-236 and MTC-164. All three follicular cell lines, however, and the original tumor tissue showed the same p53 mutation (R273H) in MOH analysis and TGGE. P53 mutations are rare in thyroid tumors, but the presence of p53 mutations indicates a poor prognosis.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Significance of P53 in human thyroid tumors. 772 41


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>